13 The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission in low risk, non-severe COVID-19 patients in the first 48 hours after symptoms onset: A structured summary of a study protocol for a randomized control pilot trial.

14 understanding viral dsrna-mediated innate immune responses at the cellular level using a rainbow trout model

15 host cell factors as antiviral targets in arenavirus infection

16 dual acting neuraminidase inhibitors open new opportunities to disrupt the lethal synergism between streptococcus pneumoniae and influenza virus

17 virus infection triggers mavs polymers of distinct molecular weight

18 kshv targeted therapy: an update on inhibitors of viral lytic replication

19 a better antiviral efficacy found in nucleos(t)ide analog (na) combinations with interferon therapy than na monotherapy for hbeag positive chronic hepatitis b: a meta-analysis

20 avances y limitaciones en el uso de los dsrna como estrategias de control y prevención de enfermedades virales en sistemas acuícolas

21 a novel small rna regulates tolerance and virulence in shigella flexneri by responding to acidic environmental changes

22 balticolid: a new 12-membered macrolide with antiviral activity from an ascomycetous fungus of marine origin

23 replication and inhibitors of enteroviruses and parechoviruses

24 in vitro inhibition of the bovine viral diarrhoea virus by the essential oil of ocimum basilicum (basil) and monoterpenes

25 gamma interferon: from antimicrobial activity to immune regulation

26 Positional Isomers of Monopegylated Interferon α-2a: Isolation, Characterization, and Biological Activity

27 A new antiviral flavone glycoside from vernonia cinerea less

28 Novel Pyrazole-Hydrazone Derivatives Containing an Isoxazole Moiety: Design, Synthesis, and Antiviral Activity

29 Antiviral Efficacy of Flavonoids against Enterovirus 71 Infection in Vitro and in Newborn Mice.

30 Viral dynamics among HCV infected patients with different genotypes treated with genotypic specific or pan-genotypic direct-acting antiviral agent combinations

31 Antiviral and immunomodulatory effects of polyphenols on macrophages infected with dengue virus serotypes 2 and 3 enhanced or not with antibodies

32 Reactivation of herpesvirus in patients with hepatitis C treated with direct-acting antiviral agents

33 Prevalence of resistance-associated substitutions to direct-acting antiviral agents in hemodialysis and renal transplant patients infected with hepatitis C virus [Erratum]

34 Clinical and virological properties of hepatitis C virus genotype 4 infection in patients treated with different direct-acting antiviral agents

35 Antiviral resistance markers in influenza virus sequences in Mexico, 2000–2017

36 Prevalence of hepatitis C virus-resistant association substitutions to direct-acting antiviral agents in treatment-naïve hepatitis C genotype 1b-infected patients in western China

37 Pegylated-interferon plus ribavirin treatment does not alter the prevalence of resistance-associated substitutions to direct-acting antivirals in HCV genotype 1a patients

38 Letermovir and inhibitors of the terminase complex: a promising new class of investigational antiviral drugs against human cytomegalovirus

39 New strategies for the treatment of hepatitis C virus infection and implications of resistance to new direct-acting antiviral agents

40 Viral dynamics among HCV infected patients with different genotypes treated with genotypic specific or pan-genotypic direct-acting antiviral agent combinations

41 Antiviral and immunomodulatory effects of polyphenols on macrophages infected with dengue virus serotypes 2 and 3 enhanced or not with antibodies

42 Viral dynamics among HCV infected patients with different genotypes treated with genotypic specific or pan-genotypic direct-acting antiviral agent combinations

43 Antiviral and immunomodulatory effects of polyphenols on macrophages infected with dengue virus serotypes 2 and 3 enhanced or not with antibodies

44 Reactivation of herpesvirus in patients with hepatitis C treated with direct-acting antiviral agents

45 Prevalence of resistance-associated substitutions to direct-acting antiviral agents in hemodialysis and renal transplant patients infected with hepatitis C virus [Erratum]

46 Clinical and virological properties of hepatitis C virus genotype 4 infection in patients treated with different direct-acting antiviral agents

47 Antiviral resistance markers in influenza virus sequences in Mexico, 2000–2017

48 Prevalence of hepatitis C virus-resistant association substitutions to direct-acting antiviral agents in treatment-naïve hepatitis C genotype 1b-infected patients in western China

49 Pegylated-interferon plus ribavirin treatment does not alter the prevalence of resistance-associated substitutions to direct-acting antivirals in HCV genotype 1a patients

50 Letermovir and inhibitors of the terminase complex: a promising new class of investigational antiviral drugs against human cytomegalovirus

51 New strategies for the treatment of hepatitis C virus infection and implications of resistance to new direct-acting antiviral agents

52 Patient characteristics and analgesic efficacy of antiviral therapy in postherpetic neuralgia.

53 What is the optimal timing of antiviral treatment in pregnant hepatitis B carrier with extremely high viral load?

54 Inoculation of specific pathogen-free chickens with an infectious bursal disease virus of the ITA genotype (G6) leads to a high and persistent viral load in lymphoid tissues and to a delayed antiviral response

55 Factors affecting the purpose suppressive antiviral therapy for patients with recurrent genital herpes

56 Development and validation of a versatile HPLC-DAD method for simultaneous determination of the antiviral drugs daclatasvir, ledipasvir, sofosbuvir and ribavirin in presence of seven potential impurities. Application to assay of dosage forms and dissolution studies

57 Discovery of novel natural flavonoids as potent antiviral candidates against hepatitis C virus NS5B polymerase.

58 The pipeline of antiviral T-cell therapy: what's in the clinic and undergoing development.

59 Physicochemical Properties Govern the Activity of Potent Antiviral Flavones.

60 hnRNPA2B1: a nuclear DNA sensor in antiviral immunity.

61 [Research on substances with antiviral activity. Carbamoyl-oxyimino derivatives of isatine and analogous heterocyclic compounds].

62 Broad-Spectrum Antiviral Activity of an Ankyrin Repeat Protein on Viral Assembly against Chimeric NL4-3 Viruses Carrying Gag/PR Derived from Circulating Strains among Northern Thai Patients

63 Efficacy of Direct-acting Antivirals for Chronic Hepatitis C Virus Infection in People Who Inject Drugs or Receive Opioid Substitution Therapy: A Systematic Review and Meta-analysis.

64 Validated spectrophotometric and chromatographic methods for analysis of the recently approved hepatitis C antiviral combination ledipasvir and sofosbuvir.

65 The health impact of delaying direct-acting antiviral treatment for chronic hepatitis C: a decision-analytic approach.

66 Investigation of Brassica juncea, Forsythia suspensa, and Inula britannica: Phytochemical properties, antiviral effects, and safety

67 Synthesis and antibacterial and antiviral activities of myricetin derivatives containing a 1,2,4-triazole Schiff base

68 Antiviral activity of itraconazole against type I feline coronavirus infection.

69 Antifungal azoles itraconazole and posaconazole exhibit potent in vitro antiviral activity against clinical isolates of parechovirus A3 (Picornaviridae).

70 Pharmacological activities of Triazole analogues as antibacterial, antifungal, antiviral agents

71 Antitumor and antiviral activities of 4-substituted 1,2,3-triazolyl-2,3-dibenzyl-L-ascorbic acid derivatives.

72 Unique synergistic antiviral effects of Shufeng Jiedu Capsule and oseltamivir in influenza A viral-induced acute exacerbation of chronic obstructive pulmonary disease.

73 Cryo-EM structure of pleconaril-resistant rhinovirus-B5 complexed to the antiviral OBR-5-340 reveals unexpected binding site.

74 Cycloartane triterpenoids from Pseudolarix amabilis and their antiviral activity.

75 Antiviral Effectors and Gene Drive Strategies for Mosquito Population Suppression or Replacement to Mitigate Arbovirus Transmission by .

76 Comparison of broad-spectrum antiviral activities of the synthetic rocaglate CR-31-B (-) and the eIF4A-inhibitor Silvestrol.

77 Design and synthesis of novel Imidazo[2,1-b]thiazole derivatives as potent antiviral and antimycobacterial agents.

78 Synthesis and evaluation of some new 1,3,4-oxadiazoles bearing thiophene, thiazole, coumarin, pyridine and pyridazine derivatives as antiviral agents.

79 Modifications in the branched arms of a class of dual inhibitors of HIV and EV71 replication expand their antiviral spectrum.

80 Antiviral activity of extracted fraction from camel urine against corona and influenza a (H1N1) viruses

81 Antiviral Innate Immune Response Interferes with the Formation of Replication-Associated Membrane Structures Induced by a Positive-Strand RNA Virus

82 HCV mono-infected and HIV/HCV co-infected individuals treated with direct-acting antivirals: to what extent do they differ?

83 Valuable antiviral therapeutic options for the treatment of chronic hepatitis C patients with thrombocytopenia.

84 Preclinical optimization of gp120 entry-antagonists as anti-HIV-1 agents with improved cytotoxicity and ADME properties through rational design, synthesis, and antiviral evaluation.

85 Antiviral Effect of Epigallocatechin Gallate via Impairing Porcine Circovirus Type 2 Attachment to Host Cell Receptor.

86 Response to direct-acting antiviral agents in chronic hepatitis C patients with end-stage renal disease: a clinical experience.

87 Enzyme-Catalyzed Kinetic Resolution of Chiral Precursors to Antiviral Prodrugs.

88 Broad Spectrum Antiviral Agent Niclosamide and Its Therapeutic Potential.

89 Structure-based stabilization of non-native protein-protein interactions of coronavirus nucleocapsid proteins in antiviral drug design

90 De Novo Design of α-Helical Lipopeptides Targeting Viral Fusion Proteins: A Promising Strategy for Relatively Broad-Spectrum Antiviral Drug Discovery

91 Emetine, Ipecac, Ipecac Alkaloids and Analogues as Potential Antiviral Agents for Coronaviruses

92 Extreme genomic CpG deficiency in SARS-CoV-2 and evasion of host antiviral defense.

93 Clinical Pharmacology Perspectives on the Antiviral Activity of Azithromycin and Use in COVID-19.

94 SARS CoV-2: Recent Reports on Antiviral Therapies Based on Lopinavir/Ritonavir, Darunavir/Umifenovir, Hydroxychloroquine, Remdesivir, Favipiravir and Other Drugs for the Treatment of the New Coronavirus.

95 Effects of infectious bursal disease virus infection on interferon and antiviral gene expression in layer chicken bursa

96 Antiviral Activity of Tannic Acid Modified Silver Nanoparticles: Potential to Activate Immune Response in Herpes Genitalis.

97 Cytomegalovirus antivirals and development of improved animal models

98 Patterns of Drug and Alcohol Use and Injection Equipment Sharing Among People With Recent Injecting Drug Use or Receiving Opioid Agonist Treatment During and Following Hepatitis C Virus Treatment With Direct-acting Antiviral Therapies: An International Study

99 Porcine antiviral activity is increased by CRISPRa-SAM system

100 Antiviral activity of C-alkylated purine nucleosides obtained by cross-coupling with tetraalkyltin reagents

101 Recombinant human eosinophil-derived neurotoxin/RNase 2 functions as an effective antiviral agent against respiratory syncytial virus

Keyword Connections

Journals

Research Groups

Bibliographies